128 related articles for article (PubMed ID: 35659150)
1. Rare Germline Variants Are Associated with Rapid Biochemical Recurrence After Radical Prostate Cancer Treatment: A Pan Prostate Cancer Group Study.
Burns D; Anokian E; Saunders EJ; Bristow RG; Fraser M; Reimand J; Schlomm T; Sauter G; Brors B; Korbel J; Weischenfeldt J; Waszak SM; Corcoran NM; Jung CH; Pope BJ; Hovens CM; Cancel-Tassin G; Cussenot O; Loda M; Sander C; Hayes VM; Dalsgaard Sorensen K; Lu YJ; Hamdy FC; Foster CS; Gnanapragasam V; Butler A; Lynch AG; Massie CE; ; Woodcock DJ; Cooper CS; Wedge DC; Brewer DS; Kote-Jarai Z; Eeles RA
Eur Urol; 2022 Aug; 82(2):201-211. PubMed ID: 35659150
[TBL] [Abstract][Full Text] [Related]
2. Are biochemical recurrence outcomes similar after radical prostatectomy and radiation therapy? Analysis of prostate cancer-specific mortality by nomogram-predicted risks of biochemical recurrence.
Lee BH; Kibel AS; Ciezki JP; Klein EA; Reddy CA; Yu C; Kattan MW; Stephenson AJ
Eur Urol; 2015 Feb; 67(2):204-9. PubMed ID: 25294696
[TBL] [Abstract][Full Text] [Related]
3. Identification of Genes with Rare Loss of Function Variants Associated with Aggressive Prostate Cancer and Survival.
Saunders EJ; Dadaev T; Brook MN; Wakerell S; Govindasami K; Rageevakumar R; Hussain N; Osborne A; Keating D; Lophatananon A; Muir KR; ; Darst BF; Conti DV; Haiman CA; Antoniou AC; Eeles RA; Kote-Jarai Z
Eur Urol Oncol; 2024 Apr; 7(2):248-257. PubMed ID: 38458890
[TBL] [Abstract][Full Text] [Related]
4. Impact of Pathogenic Germline DNA Damage Repair alterations on Response to Intense Neoadjuvant Androgen Deprivation Therapy in High-risk Localized Prostate Cancer.
Berchuck JE; Zhang Z; Silver R; Kwak L; Xie W; Lee GM; Freedman ML; Kibel AS; Van Allen EM; McKay RR; Taplin ME
Eur Urol; 2021 Sep; 80(3):295-303. PubMed ID: 33888356
[TBL] [Abstract][Full Text] [Related]
5. GBX2 Methylation Is a Novel Prognostic Biomarker and Improves Prediction of Biochemical Recurrence Among Patients with Prostate Cancer Negative for Intraductal Carcinoma and Cribriform Architecture.
Jeyapala R; Savio AJ; Olkhov-Mitsel E; Kamdar S; Zhao F; Cuizon C; Liu RSC; Zlotta A; Fleshner N; van der Kwast T; Bapat B
Eur Urol Oncol; 2019 May; 2(3):231-238. PubMed ID: 31200836
[TBL] [Abstract][Full Text] [Related]
6. Rare Germline Variants in ATM Predispose to Prostate Cancer: A PRACTICAL Consortium Study.
Karlsson Q; Brook MN; Dadaev T; Wakerell S; Saunders EJ; Muir K; Neal DE; Giles GG; MacInnis RJ; Thibodeau SN; McDonnell SK; Cannon-Albright L; Teixeira MR; Paulo P; Cardoso M; Huff C; Li D; Yao Y; Scheet P; Permuth JB; Stanford JL; Dai JY; Ostrander EA; Cussenot O; Cancel-Tassin G; Hoegel J; Herkommer K; Schleutker J; Tammela TLJ; Rathinakannan V; Sipeky C; Wiklund F; Grönberg H; Aly M; Isaacs WB; Dickinson JL; FitzGerald LM; Chua MLK; Nguyen-Dumont T; ; Schaid DJ; Southey MC; Eeles RA; Kote-Jarai Z
Eur Urol Oncol; 2021 Aug; 4(4):570-579. PubMed ID: 33436325
[TBL] [Abstract][Full Text] [Related]
7. Prediction of outcome following early salvage radiotherapy among patients with biochemical recurrence after radical prostatectomy.
Briganti A; Karnes RJ; Joniau S; Boorjian SA; Cozzarini C; Gandaglia G; Hinkelbein W; Haustermans K; Tombal B; Shariat S; Sun M; Karakiewicz PI; Montorsi F; Van Poppel H; Wiegel T
Eur Urol; 2014 Sep; 66(3):479-86. PubMed ID: 24345725
[TBL] [Abstract][Full Text] [Related]
8. Nomogram Predicting Prostate Cancer-specific Mortality for Men with Biochemical Recurrence After Radical Prostatectomy.
Brockman JA; Alanee S; Vickers AJ; Scardino PT; Wood DP; Kibel AS; Lin DW; Bianco FJ; Rabah DM; Klein EA; Ciezki JP; Gao T; Kattan MW; Stephenson AJ
Eur Urol; 2015 Jun; 67(6):1160-1167. PubMed ID: 25301759
[TBL] [Abstract][Full Text] [Related]
9. Prognostic Implications of Multiparametric Magnetic Resonance Imaging and Concomitant Systematic Biopsy in Predicting Biochemical Recurrence After Radical Prostatectomy in Prostate Cancer Patients Diagnosed with Magnetic Resonance Imaging-targeted Biopsy.
Gandaglia G; Ploussard G; Valerio M; Marra G; Moschini M; Martini A; Roumiguié M; Fossati N; Stabile A; Beauval JB; Malavaud B; Scuderi S; Barletta F; Afferi L; Rakauskas A; Gontero P; Mattei A; Montorsi F; Briganti A
Eur Urol Oncol; 2020 Dec; 3(6):739-747. PubMed ID: 32847747
[TBL] [Abstract][Full Text] [Related]
10. Risk Stratification of Patients Candidate to Radical Prostatectomy Based on Clinical and Multiparametric Magnetic Resonance Imaging Parameters: Development and External Validation of Novel Risk Groups.
Mazzone E; Gandaglia G; Ploussard G; Marra G; Valerio M; Campi R; Mari A; Minervini A; Serni S; Moschini M; Marquis A; Beauval JB; van den Bergh R; Rahota RG; Soeterik T; Roumiguiè M; Afferi L; Zhuang J; Guo H; Mattei A; Gontero P; Cucchiara V; Stabile A; Fossati N; Montorsi F; Briganti A
Eur Urol; 2022 Feb; 81(2):193-203. PubMed ID: 34399996
[TBL] [Abstract][Full Text] [Related]
11. Oncologic outcomes at 10 years following robotic radical prostatectomy.
Diaz M; Peabody JO; Kapoor V; Sammon J; Rogers CG; Stricker H; Lane Z; Gupta N; Bhandari M; Menon M
Eur Urol; 2015 Jun; 67(6):1168-1176. PubMed ID: 24996687
[TBL] [Abstract][Full Text] [Related]
12. Identification of a five gene signature to predict time to biochemical recurrence after radical prostatectomy.
Corradi JP; Cumarasamy CW; Staff I; Tortora J; Salner A; McLaughlin T; Wagner J
Prostate; 2021 Jul; 81(10):694-702. PubMed ID: 34002865
[TBL] [Abstract][Full Text] [Related]
13. TGF-β/PI3K/AKT/mTOR/NF-kB pathway. Clinicopathological features in prostate cancer.
Torrealba N; Vera R; Fraile B; Martínez-Onsurbe P; Paniagua R; Royuela M
Aging Male; 2020 Dec; 23(5):801-811. PubMed ID: 30973040
[TBL] [Abstract][Full Text] [Related]
14. Association of Inherited Mutations in DNA Repair Genes with Localized Prostate Cancer.
Lee DJ; Hausler R; Le AN; Kelly G; Powers J; Ding J; Feld E; Desai H; Morrison C; Doucette A; Gabriel P; Genetics Center R; Judy RL; Weaver J; Kember R; Damrauer SM; Rader DJ; Domchek SM; Narayan V; Schwartz LE; Maxwell KN
Eur Urol; 2022 Jun; 81(6):559-567. PubMed ID: 34711450
[TBL] [Abstract][Full Text] [Related]
15. Phosphodiesterase Type 5 Inhibitor Use and Disease Recurrence After Prostate Cancer Treatment.
Loeb S; Folkvaljon Y; Robinson D; Schlomm T; Garmo H; Stattin P
Eur Urol; 2016 Nov; 70(5):824-828. PubMed ID: 26743040
[TBL] [Abstract][Full Text] [Related]
16. Assessing the Optimal Timing for Early Salvage Radiation Therapy in Patients with Prostate-specific Antigen Rise After Radical Prostatectomy.
Fossati N; Karnes RJ; Cozzarini C; Fiorino C; Gandaglia G; Joniau S; Boorjian SA; Goldner G; Hinkelbein W; Haustermans K; Tombal B; Shariat S; Karakiewicz PI; Montorsi F; Van Poppel H; Wiegel T; Briganti A
Eur Urol; 2016 Apr; 69(4):728-733. PubMed ID: 26497924
[TBL] [Abstract][Full Text] [Related]
17. A comprehensive immunohistochemical and molecular approach to the PI3K/AKT/mTOR (phosphoinositide 3-kinase/v-akt murine thymoma viral oncogene/mammalian target of rapamycin) pathway in bladder urothelial carcinoma.
Korkolopoulou P; Levidou G; Trigka EA; Prekete N; Karlou M; Thymara I; Sakellariou S; Fragkou P; Isaiadis D; Pavlopoulos P; Patsouris E; Saetta AA
BJU Int; 2012 Dec; 110(11 Pt C):E1237-48. PubMed ID: 23107319
[TBL] [Abstract][Full Text] [Related]
18. Roles of genetic variants in the PI3K and RAS/RAF pathways in susceptibility to endometrial cancer and clinical outcomes.
Wang LE; Ma H; Hale KS; Yin M; Meyer LA; Liu H; Li J; Lu KH; Hennessy BT; Li X; Spitz MR; Wei Q; Mills GB
J Cancer Res Clin Oncol; 2012 Mar; 138(3):377-85. PubMed ID: 22146979
[TBL] [Abstract][Full Text] [Related]
19. Germline genetic variants in men with prostate cancer and one or more additional cancers.
Pilié PG; Johnson AM; Hanson KL; Dayno ME; Kapron AL; Stoffel EM; Cooney KA
Cancer; 2017 Oct; 123(20):3925-3932. PubMed ID: 28657667
[TBL] [Abstract][Full Text] [Related]
20. Defining the Most Informative Intermediate Clinical Endpoints for Predicting Overall Survival in Patients Treated with Radical Prostatectomy for High-risk Prostate Cancer.
Martini A; Gandaglia G; Karnes RJ; Zaffuto E; Bianchi M; Gontero P; Chlosta P; Gratzke C; Graefen M; Tilki D; Cucchiara V; Mirone V; Kneitz B; Sanchez Salas R; Van Der Poel H; Tombal B; Spahn M; Joniau TS; Montorsi F; Briganti A;
Eur Urol Oncol; 2019 Jul; 2(4):456-463. PubMed ID: 31277783
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
